Last update May 13, 2019
Follicle stimulating hormone (FSH) or follitropin is a hormone of the gonadotropin type, which is found normally in the body. It is synthesized and secreted by gonadotroph cells from the anterior part of the pituitary gland.
FSH regulates pubertal maturation. In women, it matures the oocytes of the ovary and stimulates the production of estradiol (estrogen hormone). In men it regulates the production of sperm.
CORIFOLITROPIN is an FSH obtained by recombinant engineering, like follitropin alpha, beta and delta. Its efficacy and indications are the same, but as it is long-acting, it is more comfortable and reduces the number of injections (Benchabane 2017, Cruz 2017, Griesinger 2016).
It is used in infertility treatments to induce ovulation in anovulatory patients and for the development of multiple follicles (ovarian hyperstimulation) in ovulatory patients in assisted reproduction programmes.
Subcutaneous administration in a single dose. Subsequently (after 5-6 days) the human chorionic gonadotropin (hCG) is administered to trigger ovulation.
Since the last update we have not found any published data on its excretion in breast milk.
Its high molecular weight makes its excretion in breastmilk very unlikely.
Due to its proteinaceous nature it is inactivated in the gastrointestinal tract, not being absorbed, (oral bioavailability is practically zero), which impedes transfer to infant plasma from breastmilk, except in premature babies and the immediate neonatal period, when there may be more intestinal permeability.
There is no proof that its estrogenic effects decrease milk production.
BREASTFEEDING and INFERTILITY TREATMENTS
In assisted reproduction treatments (ART) for infertility, two issues must be taken into account:
1. The possible effects of ART on the infant or breastfeeding.
The medication used, in general, does not interfere with breastfeeding and does not affect the infant, who in these cases is usually older than 6 months and even 1 or 2 years old.
2. The possible interference of breastfeeding with ART.
Breastfeeding, especially frequent, could hinder ovulation. This is the main reason why assisted reproduction services recommend suspending breastfeeding before starting treatment which is usually emotionally costly and, often, also from a financial perspective.
To date, there is no published data that proves that breastfeeding is incompatible with assisted reproduction techniques (ART).
We do not have alternatives for Corifollitropin Alfa.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM